Sanofi Improperly Listed Lantus Patent In FDA's Orange Book, Appeals Court Finds

First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.

Justice in front of Law
Appeals court revives antitrust claims against Sanofi for improper patent listing in FDA's Orange Book

More from Legal & IP

More from Pink Sheet